Table 2 Patient demographics
Derivation cohort | Validation cohort | |||
|---|---|---|---|---|
Full cohort for death (n = 2437) | Subset for potential to benefit (n = 398) | Full cohort for death (n = 2322) | Subset for potential to benefit (n = 227) | |
Variable | Mean (sd; range) | |||
Age | 69 (19; 18–103) | 66.5 (20.2; 18–102) | 70 (19; 18–103) | 71.3 (18.3; 19–96) |
Respiratory rate | 19 (6;6–60) | 20 (7; 6–45) | 20 (6.6; 8–80) | 20 (5.8; 12–40) |
Systolic BP | 136 (29; 24–266) | 133 (29; 45–243) | 139 (28.4; 44–261) | 138 (28.6; 60–249) |
Diastolic BP | 75 (15; 30–153) | 75 (15; 36–130) | 76 (15; 11–151) | 74 (15; 36–142) |
Pulse rate | 88 (24; 21–215) | 92 (24; 35–188) | 88 (23; 20–180) | 89 (21.9; 35–152) |
Temperature | 36.6 (1.2; 26.0–41.0) | 36.5 (1.2; 26.0–40.0) | 36.5 (1.1; 25.2–40.5) | 36.6 (1.40; 26.4–39.6) |
Variable | Median (IQR; range) | |||
SaO2 breathing air | 97 (95–98; 50–100) | 97 (94–98; 66–100) | 97 (95–98; 45–100) | 96 (94–98; 45–100) |
SaO2 breathing oxygen | 98 (95–100; 24–100) | 97 (96–99; 71–100) | 98 (95–100; 60–100) | 98 (96–100; 84–100) |
GCS | 15 (15–15; 3–15) | 15 (15–15; 3–15) | 15 (15–15; 3–15) | 15 (15–15; 7–15) |
Variable | Number (percentage) | |||
Male | 1131 (46.4) | 183 (46) | 1093 (46.5) | 95 (42) |
Active malignancy | 110 (4.5) | 23 (5.8) | 96 (4.1) | 6 (2.7) |
Outcomes | Number (percentage) | |||
All deaths | 128 (5.2) | 141 (6.0) | ||
Inevitable death | 15 (3.7) | 2 (0.8) | ||
Potentially preventable death | 5 (1.2) | 1 (0.4) | ||
Prevented death | 79 (19.8) | 35 (15.4) | ||